The Clinical Significance of Interleukin-6 in Heart Failure: Results from the BIOSTAT-CHF Study
George Markousis‐Mavrogenis(University Medical Center Groningen), Peter van der Meer(University Medical Center Groningen), Pim van der Harst(Utrecht University), Gerasimos Filippatos(National and Kapodistrian University of Athens), Hans L. Hillege(University Medical Center Groningen), Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy), Wouter Ouwerkerk(University of Amsterdam), Aeilko H. Zwinderman(Amsterdam Neuroscience), Marco Metra(Vita-Salute San Raffaele University), Chim C. Lang(University of Dundee), Jasper Tromp(Duke-NUS Medical School), Adriaan A. Voors(University Medical Center Groningen), Rahul Kakkar(AstraZeneca (United States)), Leong L. Ng(University of Leicester), Nilesh J. Samani(University of Leicester), Kenneth Dickstein, Matt Devalaraja(AstraZeneca (United States)), Dirk Jan van Veldhuisen(University of Groningen), John G.F. Cleland(University of Glasgow), Stefan D. Anker(Universitätsmedizin Göttingen), Piotr Ponikowski(Wroclaw Medical University)
Cited by 281
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
|European Journal of Heart Failure|2016|5.9k